Misoprostol as a Treatment for Endometrial Polyps in Infertile Patients

Misoprotol as a Treatment for Endometrial Polyps in Infertile Patients

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04270994

Enrollment

Registered

2020-02-17

Start date

2016-09-30

Completion date

2019-11-30

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Polyps in Infertile Patients

Brief summary

Endometrial polyps are one of the main causes of infertility in women. In this work we propose an alternative, effective, economical and safe treatment: the use of misoprostol

Detailed description

The prevalence of uterine polyps has been estimated in the general population at 10-15%, while in infertile patients it ranges from 6-32%. Its etiology is considered as multifactorial. Polyps induce a local inflammatory response in the endometrial cavity, causing infertility. The treatment of choice considered gold standard is the excision by hysteroscopy, however, improvement has been shown in patients with conservative management due to the regression rate of 27%. There are no recommended drugs to provide a definitive treatment for uterine polyps. Misoprostol is a synthetic analogue derived from prostaglandin E1 that has stimulating effects on the smooth muscle fibers of the uterus, causing contractions of the myometrium, which cause endouterine evacuation. The present study shows a possible utility of misoprostol for the conservative treatment of uterine polyps.

Interventions

DRUGMisoprostol

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Women with uterine polyps diagnosed by endovaginal ultrasound and/or hysterosonography, female ≤ 45 years of age

Exclusion criteria

* Patients older than 45 years, polyps larger than 60 mm, who did not perform surveillance and/or minimum assessment 6 months after medical management

Design outcomes

Primary

Measure	Time frame
Expulsion rate of endometrial polyps	7 days after misoprostol has been applied

Secondary

Measure	Time frame
Pregnancy rate after expulsion	14-21 days after positive β-human Chorionic Gonadotropin (β-hCG)
The pregnancy rate after expulsion in patients with primary sterility	14-21 days after positive β-hCG

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026